Lupin launches triple-therapy inhaler for COPD in India
In short
Lupin launched Formoflo-G MDI in India for COPD. The inhaler uses three established medicines in one twice-daily device, and it got DCGI approval.
This could matter to COPD patients and Lupin’s respiratory business. The report does not say the price, launch timing, or expected sales.
What the reporting says
Lupin launched Formoflo-G MDI, a fixed-dose triple-combination inhaler for COPD in India, after DCGI approval. The publisher-supplied summary says the inhaler combines three established therapies and is taken twice daily. It also notes India has a large COPD patient pool. The reporting does not state sales targets, pricing, or the launch date.
Why it matters
Lupin launched Formoflo-G MDI in India for COPD, using a fixed-dose triple combination and a twice-daily dosing schedule after DCGI approval. The summary says the product targets India’s large COPD patient pool. The reporting does not say how many patients it may reach, the price, or whether the launch will change Lupin’s revenues soon.